26,363 Danaher Corporation $DHR Shares Acquired by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC grew its stake in Danaher Corporation (NYSE:DHR) by 181.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 40,855 shares of the conglomerate’s stock after acquiring an additional 26,363 shares during the period. Frank Rimerman Advisors LLC’s holdings in Danaher were worth $9,051,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Gunderson Capital Management LLC acquired a new stake in shares of Danaher in the third quarter valued at $765,000. EP Wealth Advisors LLC purchased a new stake in shares of Danaher in the 2nd quarter valued at $3,807,000. Beaumont Asset Management L.L.C. acquired a new position in Danaher during the 3rd quarter worth about $1,685,000. Banque Pictet & Cie SA lifted its stake in Danaher by 23.4% during the 3rd quarter. Banque Pictet & Cie SA now owns 145,326 shares of the conglomerate’s stock worth $32,197,000 after acquiring an additional 27,534 shares in the last quarter. Finally, Baugh & Associates LLC purchased a new position in Danaher during the 3rd quarter valued at about $16,100,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE:DHR opened at $228.87 on Friday. The company has a fifty day simple moving average of $214.04 and a two-hundred day simple moving average of $195.97. The company has a market cap of $160.89 billion, a price-to-earnings ratio of 40.65, a price-to-earnings-growth ratio of 2.88 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 earnings per share. As a group, equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Analysts Set New Price Targets

Several research firms have weighed in on DHR. Stifel Nicolaus dropped their target price on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Wells Fargo & Company cut their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. TD Cowen increased their price target on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley raised their price objective on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Finally, Guggenheim raised their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.